Patent · US Active

Synthetic linear apelin mimetics for the treatment of heart failure

US10005829B2 · kind B2 · utility

3Cited by

10References

20Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Frederic Zecri · Cambridge, US
Kayo Yasoshima · Cambridge, US
Philipp Grosche · Inzlingen, DE
Jun Yuan · Guilford, US
Hongjuan Zhao · Lexington, US

Key dates

Filing date	Nov 19, 2013
Grant date	Jun 26, 2018
Priority date	—
Expiry date	May 15, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/47
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to novel compositions comprising modified apelin-13 peptide sequences designed to treat cardiovascular disease in subjects to whom they are administered, and which exhibit greater resistance to degradation, and equivalent or greater bioactivity than their wild type counterparts. The invention also relates to methods of making said compositions and using said compositions as pharmaceutically active agents to treat cardiovascular disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.